<FONT SIZE = "150"
Vita 34, the first private Umbilical Blood Bank in Europe, has received authorization to use these cells autologously within the framework of a clinical study with children diagnosed with type 1 diabetes.
Secuvita customers, whose children have developed the disease, will have the opportunity to be part of this analytical study, the Spanish company has reported today in a press release.
The essay, which will last twenty -four months with a control group, will be carried out by the Institute for Research on Diabetes of the Children's and Youth Clinic and Polyclinics of the Technical University of Munich.
The authorization has been granted by the Paul-Ehrlich Institute, under the Ministry of Health, as a competent German body.
The purpose of the investigation aims to determine the potential security and efficacy of a blood transfusion of the own umbilical cord, of recently diagnosed children with type 1 diabetes.
An analogous pilot study in the United States has shown very promising results regarding the altered immune balance, to the need for insulin and the quality of metabolism control.
Other previous works carried out by the American Diabetes Association have revealed very positive results in the face of stem cell treatments, among which especially the possibility of helping to regulate the autoimmune response that characterizes this pathology.
Dr. Pérez de Oteyza has explained that the approval now of a new clinical trial in Germany will increase the number of cases treated and thus obtain more representative data on the real umbility of umbilical cord cells in the treatment of diabetes.
In addition, he pointed out that since it is a prospective, controlled protocol and with a control group, the results that are achieved will predictably have a greater statistical significance.
Next to the bone marrow or peripheral blood, the blood of the umbilical cord represents an increasingly important source for obtaining stem cells.
These can be used potentially in a wide range of indications and at the moment there are very specific fields of application, such as different carcinogenic diseases and the immune system, and in the field of regenerative medicine.